Severe, symptomatic, dose-limiting hypophosphatemia induced by hepatic arterial infusion of recombinant tumor necrosis factor in patients with liver metastases
✍ Scribed by Auro Del Giglio; Giora M. Mavligit; Alexander A. Zukiwski; Mohamed K. Ali
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 289 KB
- Volume
- 67
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Twenty-two patients with liver metastases received 45 courses of recombinant tumor necrosis factor (rTNF] by hepatic arterial infusion in doses ranging from 12.5 to 175 pg/m2/d for 5 days by continuous infusion. The induction of statistically significant, dose-related, severe, albeit transient, hypophosphatemia (< 1.0 mg/dl) associated with clinically significant, right-sided myocardial dysfunction and severe lassitude q a s observed. These side effects were promptly reversed after rTNF was stopped and intravenous phosphate supplementation was started. As no significant or consistent increase in urinary phosphate excretion was detected, the rTNFinduced hypophosphatemia probably resulted from an intracellular shift of phosphate. Since tumor regression was clearly associated with the lowest levels of serum phosphate, hypophosphatemia may be important in the antitumor effects of rTNF. Cancer 672459-2461.1991.
ECOMBINANT TUMOR NECROSIS FACTOR (rTNF) is
From the